76 related articles for article (PubMed ID: 36481378)
1. Diagnosis of mycosis fungoides or Sézary syndrome after dupilumab use: A systematic review.
Jfri A; Smith JS; Larocca C
J Am Acad Dermatol; 2023 May; 88(5):1164-1166. PubMed ID: 36481378
[No Abstract] [Full Text] [Related]
2. Dupilumab, Atopic Dermatitis, and Mycosis Fungoides-New Insights on an Evolving Story.
Guitart J
JAMA Dermatol; 2023 Nov; 159(11):1177-1178. PubMed ID: 37851433
[No Abstract] [Full Text] [Related]
3. Changes to Registered and Pivotal Clinical Trials after the 2011 Tri-Societies Guidelines for Clinical Endpoints and Response Criteria in Mycosis Fungoides and Sézary Syndrome.
Gunter SJ; Kim EJ
J Invest Dermatol; 2024 Apr; 144(4):855-861.e1. PubMed ID: 37925066
[TBL] [Abstract][Full Text] [Related]
4. Advancements in the treatment of mycosis fungoides and Sézary syndrome: monoclonal antibodies, immunotherapies, and Janus kinase inhibitors.
Quadri I; Reneau JC; Hanel W; Chung CG
Front Immunol; 2023; 14():1291259. PubMed ID: 38022633
[TBL] [Abstract][Full Text] [Related]
5. Mycosis fungoides and Sézary syndrome following dupilumab treatment: experience of two Italian tertiary care centres.
Buffon S; Alberti Violetti S; Avallone G; Venegoni L; Marzano AV; Mastorino L; Fava P; Ribero S; Quaglino P; Ortoncelli M; Ferrucci SM
Clin Exp Dermatol; 2023 Nov; 48(12):1376-1378. PubMed ID: 37596961
[No Abstract] [Full Text] [Related]
6. Overall survival in the UK in mycosis fungoides or Sézary syndrome cutaneous T-cell lymphoma: comparative effectiveness of mogamulizumab versus current standard of care.
Hawkins N; Muszbek N; Evans R; McNamara L; Jones T
J Comp Eff Res; 2023 Oct; 12(10):e230017. PubMed ID: 37642410
[No Abstract] [Full Text] [Related]
7. Mogamulizumab combined with extracorporeal photopheresis for the treatment of refractory mycosis fungoides and Sézary syndrome. Report of seven cases.
Rubio-Muniz CA; Sánchez-Velázquez A; Arroyo-Andrés J; Agud-de Dios M; Tarín-Vicente EJ; Falkenhain-López D; Ortiz-Romero PL
J Eur Acad Dermatol Venereol; 2024 Jan; 38(1):e102-e105. PubMed ID: 37611255
[No Abstract] [Full Text] [Related]
8. Severely pruritic mycosis fungoides successfully treated with upadacitinib.
Kook H; Park SY; Hong N; Lee DH; Jung HJ; Park MY; Ahn J
J Dtsch Dermatol Ges; 2024 Mar; 22(3):450-451. PubMed ID: 38326084
[No Abstract] [Full Text] [Related]
9. The biomarker landscape in mycosis fungoides and Sézary syndrome.
Dulmage B; Geskin L; Guitart J; Akilov OE
Exp Dermatol; 2017 Aug; 26(8):668-676. PubMed ID: 27897325
[TBL] [Abstract][Full Text] [Related]
10. Inflammatory arthritis complicating mogamulizumab treatment of Sézary syndrome.
Bass AR; Sama ML
Rheumatology (Oxford); 2024 Mar; 63(3):e113-e114. PubMed ID: 37846040
[No Abstract] [Full Text] [Related]
11. Journal Club: Mycosis fungoides and Sézary syndrome: an update on a classic disease.
González DV; Rosell-Díaz ÁM; Chircop I; Lé AM; Dege T; Byrne N; Reynaud V; García-Piqueras P
Eur J Dermatol; 2023 Dec; 33(6):714-718. PubMed ID: 38465567
[No Abstract] [Full Text] [Related]
12. Dermatomyositis versus mycosis fungoides: Challenges in the diagnosis of erythroderma with associated myositis.
Masson A; Ram-Wolff C; Bouaziz JD; Cayuela JM; Lorillon G; Frumholtz L; Cassius C; Petit A; Léonard-Louis S; Battistella M; Vignon-Pennamen MD; Rivet J; Meignin V; Duverger L; Jachiet M; Bagot M; Lazaridou I
Ann Dermatol Venereol; 2023 Jun; 150(2):129-133. PubMed ID: 36682974
[No Abstract] [Full Text] [Related]
13. Dupilumab-Associated Sezary Syndrome.
Hamp A; Hanson J; Alhatem A; Schwartz RA
Indian J Dermatol; 2023; 68(4):459-462. PubMed ID: 37822402
[TBL] [Abstract][Full Text] [Related]
14. Sezary Syndrome: A Case Report and Review of Current Therapeutics.
Krishnan J; Thanikachalam K
Cureus; 2024 Apr; 16(4):e58570. PubMed ID: 38765439
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors in mycosis fungoides: international advances in the validation of prognostic indices.
Scarisbrick JJ
Br J Dermatol; 2017 May; 176(5):1129-1130. PubMed ID: 28504404
[No Abstract] [Full Text] [Related]
16. Reply to letter to the editor (Manuscript # JAAD-D-22-03011R1).
LeWitt TM; Walker CJ; Espinosa ML; Chung C; Zhou XA; Guitart J
J Am Acad Dermatol; 2023 Jul; 89(1):e67. PubMed ID: 36948297
[No Abstract] [Full Text] [Related]
17. Alemtuzumab as first- and second-line treatment in patients with Sézary syndrome-The experience of a tertiary centre.
Nogueira M; Lau C; Teixeira MDA; Peixeiro R; Cabral R; Fernandes I
J Eur Acad Dermatol Venereol; 2024 Jan; 38(1):e86-e88. PubMed ID: 37595960
[No Abstract] [Full Text] [Related]
18. Clinical characteristics, initial treatment, and prognosis of mycosis fungoides and Sézary syndrome: A retrospective, single-center study at the Centre Hospitalier Universitaire of Quebec.
Lachance M; Thibeault MM
Ann Dermatol Venereol; 2023 Dec; 150(4):276-280. PubMed ID: 37777355
[No Abstract] [Full Text] [Related]
19. Dupilumab as Effective Therapy for Corticosteroid- Dependent/Resistant Type 2 Inflammation-Related Cutaneous Adverse Reactions.
Shen C; Wu N; Yang L; Wang B; Liu T; Tao J
J Investig Allergol Clin Immunol; 2024 Apr; 34(2):145-147. PubMed ID: 38639452
[No Abstract] [Full Text] [Related]
20. A Case of Sézary Syndrome in a Patient Treated with Dupilumab for Atopic Dermatitis.
Muramatsu K; Ikutama R; Hasegawa T
Indian J Dermatol; 2024; 69(2):184-187. PubMed ID: 38841235
[No Abstract] [Full Text] [Related]
[Next] [New Search]
